<DOC>
	<DOCNO>NCT00882921</DOCNO>
	<brief_summary>The objective study evaluate effect anti-idursulfase antibody idursulfase safety ( measure infusion related adverse event ) patient develop anti-idursulfase antibody patient long-term idursulfase enzyme replacement therapy ( ERT ) .</brief_summary>
	<brief_title>An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response Hunter Syndrome Patients</brief_title>
	<detailed_description>This study conduct satisfy post-marketing commitment monitor anti-idursulfase antibody development Hunter syndrome patient long-term idursulfase enzyme replacement therapy . The study conduct sub-study within Hunter Outcome Survey ( HOS ) . Hunter syndrome patient HOS previously receive idursulfase well treatment-naive patient begin idursulfase treatment within 30 day study enrollment include .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Patients must meet follow criterion consider eligible enrollment : The patient male enrol HOS ( i.e. , meet entry criterion document diagnosis Hunter syndrome ) The patient â‰¥ 5 yearsold The patient idursulfase treatment schedule begin idursulfase treatment within 30 day study enrollment The patient , patient 's parent ( ) , patient 's legally authorized guardian must voluntarily sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve informed consent form relevant aspect study explain discussed patient , patient 's parent ( ) , patient 's legally authorize guardian . Patients meet follow criterion eligible study : The patient receive biologic/ERT product idursulfase , investigational product ( ) reason within 30 day prior study entry . The patient life expectancy &lt; 2 year The patient unable comply protocol , e.g. , clinically relevant medical condition make implementation protocol difficult ; uncooperative attitude ; unable return safety evaluation ; otherwise unlikely complete study , determine Investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>hunter syndrome</keyword>
	<keyword>hunter 's syndrome</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter 's disease</keyword>
	<keyword>MPS II</keyword>
	<keyword>MPSII</keyword>
	<keyword>MPS2</keyword>
	<keyword>MPS 2</keyword>
	<keyword>mucopolysaccharide</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>chronic ear infection</keyword>
	<keyword>enlarged adenoid</keyword>
	<keyword>mp symptom</keyword>
	<keyword>mp diagnosis</keyword>
	<keyword>mp ii therapy</keyword>
	<keyword>MPS II treatment</keyword>
	<keyword>ert treatment</keyword>
	<keyword>elaprase</keyword>
	<keyword>idursulfase</keyword>
	<keyword>iduronate sulfatase</keyword>
	<keyword>iduronate 2 sulfatase</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>hunter syndrome treatment</keyword>
	<keyword>hunter 's syndrome treatment</keyword>
	<keyword>hunter syndrome therapy</keyword>
	<keyword>hunter 's disease treatment</keyword>
	<keyword>mp society</keyword>
</DOC>